

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208 (b)(3)**

Nelson Watts, M.D.

**Committees:** Cardiovascular and Renal Drugs Advisory Committee

**Meeting Date:** October 16, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to all official matters concerning regulatory considerations for extending the use of phosphate binders, from the dialysis population (where they are approved) to the pre-dialysis population (where no products are approved), I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3). The committee will hear presentations on this topic from Shire Development, Genzyme Corporation, and Fresenius Medical Care.

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Unrelated Consulting	Affected Firm	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

\_\_\_\_\_  
/s/  
Signature of SGE

\_\_\_\_\_  
8/30/07  
Date